tri-cyclen and Overweight

tri-cyclen has been researched along with Overweight* in 1 studies

Trials

1 trial(s) available for tri-cyclen and Overweight

Article	Year
Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and sterility, 2011, Volume: 96, Issue:2 In this randomized, double-blind, placebo-controlled study, 19 overweight women with polycystic ovary syndrome were randomized to a 3-month course of either metformin plus combined hormonal oral contraceptive (OC) (n = 9) or OC plus matched placebo (n = 10). After 3 months, both treatments had similar effects on androgen levels, lipid profile, insulin sensitivity, and serum inflammatory markers, but flow-mediated dilatation increased by 69.0% in the metformin plus OC group while it remained unchanged in the OC group. CLINICAL TRIAL REGISTRATION NO: NCT00682890. Topics: Analysis of Variance; Biomarkers; Blood Glucose; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Endothelium, Vascular; Ethinyl Estradiol; Female; Gonadal Steroid Hormones; Humans; Hypoglycemic Agents; Inflammation Mediators; Insulin; Insulin Resistance; Lipids; Metformin; Norgestrel; Obesity; Overweight; Placebo Effect; Polycystic Ovary Syndrome; Time Factors; Treatment Outcome; Vasodilation; Virginia	2011

Article

Year

Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome.

Fertility and sterility, 2011, Volume: 96, Issue:2

In this randomized, double-blind, placebo-controlled study, 19 overweight women with polycystic ovary syndrome were randomized to a 3-month course of either metformin plus combined hormonal oral contraceptive (OC) (n = 9) or OC plus matched placebo (n = 10). After 3 months, both treatments had similar effects on androgen levels, lipid profile, insulin sensitivity, and serum inflammatory markers, but flow-mediated dilatation increased by 69.0% in the metformin plus OC group while it remained unchanged in the OC group. CLINICAL TRIAL REGISTRATION NO: NCT00682890.

Topics: Analysis of Variance; Biomarkers; Blood Glucose; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Endothelium, Vascular; Ethinyl Estradiol; Female; Gonadal Steroid Hormones; Humans; Hypoglycemic Agents; Inflammation Mediators; Insulin; Insulin Resistance; Lipids; Metformin; Norgestrel; Obesity; Overweight; Placebo Effect; Polycystic Ovary Syndrome; Time Factors; Treatment Outcome; Vasodilation; Virginia

2011